The GLP-1 based medications FDA-approved for weight loss are Wegovy (semaglutide, as a weekly injection and a daily tablet), Zepbound (tirzepatide, a weekly injection), Saxenda (liraglutide, a daily injection), and Foundayo (orforglipron, a daily pill approved in April 2026). Ozempic, Mounjaro, Victoza, Rybelsus, and Trulicity are approved for diabetes, so using them for weight loss is off-label.
GLP-1 Medications Approved for Weight Management
The Obesity Society’s medication summary lists average weight loss in each drug’s pivotal trial, compared with placebo. These come from different studies, so they are not a head-to-head ranking.
- Wegovy injection (weekly): 14.9% versus 2.4% at 68 weeks. Approved for ages 12 and older with obesity, and adults with overweight plus a weight-related condition.
- Wegovy tablets (daily): 13.6% versus 2.2% at 64 weeks, for adults.
- Zepbound (weekly): 20.9% on the 15 mg dose versus 3.1% at 72 weeks, for adults.
- Saxenda (daily): 8.0% versus 2.6% at 56 weeks, for ages 12 and older who weigh over 60 kg, and adults with overweight plus a comorbidity.
The newest addition is Foundayo. Healio reported that the FDA approved this oral GLP-1 (orforglipron) from Eli Lilly on April 1, 2026, for adults with obesity or overweight plus weight-related conditions. It is taken once daily with no food or water restrictions, and in a 72-week trial average weight loss ranged from 7.8% to 12.4% depending on the dose.
Technically, Zepbound’s tirzepatide activates both GIP and GLP-1 receptors, as Cleveland Clinic explains, but it is commonly grouped with GLP-1 medications. The drugs also differ in how you take them: weekly injections (Wegovy and Zepbound), a daily injection (Saxenda), and daily pills (Wegovy tablets and Foundayo).
Extra Approved Uses Beyond Weight Loss
Several of these drugs carry additional approvals. The Wegovy FDA label also lists cardiovascular risk reduction in adults with established heart disease and obesity or overweight, and, for the injection, treatment of MASH with moderate to advanced liver fibrosis in adults. Zepbound is also approved for moderate to severe obstructive sleep apnea in adults with obesity, as covered in its FDA label.
GLP-1 Medications Approved for Diabetes, Not Weight Loss
Ozempic, Mounjaro, Victoza, Rybelsus, and Trulicity are approved for type 2 diabetes. Cleveland Clinic points out that some people lose weight on Ozempic, but Wegovy is the semaglutide product approved for it. The Obesity Society’s summary likewise treats Victoza, Ozempic, and Mounjaro as diabetes formulations of the same molecules.
Doctors sometimes prescribe them off-label for weight loss. Cleveland Clinic also cautions that compounded versions of semaglutide are not regulated for potency, so you cannot be sure what you are getting.
Non-GLP-1 Weight Loss Medications
Three other FDA-approved options work differently, according to the Obesity Society: orlistat (Xenical), phentermine-topiramate (Qsymia), and naltrexone-bupropion (Contrave). Average losses in their pivotal trials were 10.2%, 10.9%, and 6.4% respectively, versus 6.1%, 1.6%, and 1.2% on placebo.
Who Qualifies for a Weight Loss Medication?
Labels use descriptive terms rather than a single cutoff: obesity, or overweight with at least one weight-related condition such as high blood pressure. In the STEP 1 trial that supported Wegovy, adults qualified with a BMI of 30 or greater, or 27 or greater with at least one weight-related coexisting condition. Your provider will weigh your health history, other medications, and goals, and will check whether any warnings, such as a personal or family history of medullary thyroid cancer, rule out a particular drug.
Choosing Among Your Options
Schedule, route, age, cost, coverage, and side effects all matter, alongside average results. The best match is individual, so bring these questions to your provider. If you are curious about non-prescription routes, read our guide on whether you can boost GLP-1 without a prescription. This article is for general education and is not a substitute for personalized medical advice.
Frequently Asked Questions
Is Ozempic Approved for Weight Loss?
No. Ozempic is approved for type 2 diabetes and related heart and kidney uses. Wegovy is the semaglutide product approved for weight management.
Which GLP-1 Medication Produces the Most Weight Loss?
In pivotal trials, Zepbound showed the largest average loss, but the trials differ, so results cannot be compared directly.
Are There FDA-Approved GLP-1 Pills for Weight Loss?
Yes. Wegovy tablets and Foundayo (orforglipron) are oral GLP-1 medications approved for weight management in adults.